Relative quantification of Glycoprotein at the Site Specific Glycosylation Level
Understanding the function of glycoproteins and their changes associated with the disease is complicated by challenges related to analysis and characterization. CD BioGlyco is proficient at relative quantification of glycoproteins at site-specific glycosylation levels to help researchers understand the pathogenesis of diseases.
Introduction
Protein glycosylation, the process by which glycans are transferred to proteins by the action of glycosyltransferases and form glycosidic bonds with specific amino acid residues on proteins, consists of a distribution of associated glycoforms at each glycosylation site. Since the biosynthetic substrate concentration and translocation rate are related to structure and other aspects of cellular phenotypes, site-specific glycosylation cannot be accurately predicted from the information of genomic, transcriptomic, or proteomic. Rather, it is critical to relative quantify glycosylation at each specific protein site to provide information on disease mechanisms.
At present, well-established mass spectrometry-based methods allow for relative quantification of glycosylation sites and glycan composition of singly glycosylated proteolytic peptides. To make such quantitative comparisons, it is essential to sample glycosylation distributions with accuracy and sufficient coverage to provide a reliable assessment of glycosylation changes occurring in biological cohorts.
Core Technologies
Our company leverages state-of-the-art technologies to deliver highly accurate and sensitive relative quantification of site-specific glycoprotein glycosylation. Our core technologies primarily revolves around advanced mass spectrometry (MS) coupled with sophisticated chromatographic separation techniques.
- High-Resolution, Accurate-Mass (HRAM) MS
We employ cutting-edge mass spectrometers, enabling unparalleled sensitivity and mass accuracy for the detection and characterization of intact glycopeptides. To achieve comprehensive glycopeptide characterization, we utilize a combination of fragmentation methods, including higher-energy collisional dissociation (HCD), electron transfer dissociation (ETD), and electron-transfer higher-energy collisional dissociation (EThcD). - Liquid Chromatography (LC) for Glycopeptide Separation
Our workflows incorporate advanced liquid chromatography systems, including nano-LC and ultra-high performance liquid chromatography (UCPLC), with various column chemistries such as C18, hydrophilic interaction liquid chromatography (HILIC), and porous graphitized carbon (PGC).
Our Services
CD BioGlyco provides a variety of technology platforms for the relative quantification of glycoprotein at the site-specific glycosylation level. The strategies we provide include but are not limited to:
- N-linked site mapping.
- Use endo-F or H enzymes to release the N-glycans and leave a GlcNAc core attached to the glycopeptide. Then mapping the position of the remaining GlcNAc by LC-MS allowed us to obtain information on site location as well as site occupancy.
- The asparagine residues at the N-glycosylation site of the glycopeptide are converted to aspartic acid by enzymatic deglycosylation, which increases the mass of the peptide on the N-glycosylation site thereby enabling recognition of the glycosylation site. However, confidence can be added by performing this deglycosylation reaction in "heavy" water (18O water), which increases the mass even more. The positions of the 18O-labeled aspartate residues are then mapped by LC-MS.
- O-linked site mapping by BEMAD. The reductive β-elimination of the O-glycan leaves a modified threonine or serine residue in the pre-glycopeptide. This residue is reactive to the thiol functional group and this property is utilized in the BEMAD method to label this residue for unambiguous MS detection.
- Multiple reaction monitoring (MRM), parallel reaction monitoring (PRM), selective reaction monitoring (SRM), and other mass spectrometry (MS)-based techniques such as LC-MS/MS-MRM are also effective approaches for quantifying site-specific glycosylation of glycoproteins.
Workflow

Applications
- Our service can be used as a highly specific biomarker to identify altered glycosylation patterns on specific proteins.
- Our service can be used to elucidate the precise role of individual glycosylation sites in protein function, stability, and cell interactions.
- Our services can be used to characterize the glycosylation of viral or bacterial surface proteins to understand immune escape mechanisms and design more effective vaccines.
Advantages of Us
- Our advanced MS and tailored workflows provide exceptional precision in identifying and quantifying glycosylation at individual amino acid residues. This level of detail is crucial for understanding the functional impact of specific glycan modifications.
- We employ optimized sample preparation protocols, highly efficient enrichment methods, and cutting-edge instrumentation to achieve high sensitivity, enabling the detection and quantification of even low-abundance glycopeptides.
- Our multi-fragmentation strategies (HCD, ETD, EThcD) coupled with diverse chromatographic separation techniques maximize the identification and characterization of a wide range of N-linked and O-linked glycopeptides, providing a more complete picture of the glycoproteome.
Publication Data
Technology: Time-of-flight mass spectrometer (TimsTOF), Tandem mass spectrometry (MS/MS), Western blot
Journal: Communications Biology
Published: 2023
IF: 5.1
Results: In this study, researchers conducted a comparative analysis of the site-specific N-glycoproteome of colon cancer human colorectal adenocarcinoma (HCT116) cells and their homologous non-tumorigenic DNMT1/3b double knockout (DKO1) cells. The authors discovered significant N-glycosylation abnormalities in HCT116 cells, particularly high salicylate and high mannose-6-phosphate (M6P) modifications. This study revealed the potential mechanism of M6P modification in cancer, providing new insights into the discovery of cancer biomarkers and the role of the M6P pathway in cancer.
Fig.1 Visualization of N-glycoproteinomics data. (Chen, et al., 2023)
Frequently Asked Questions
CD BioGlyco is a company with extensive experience and a good reputation in the field of glycobiology. Our advanced experimental platforms and well-trained researchers will greatly accelerate our clients' research in glycobiology. If you have a demand for relative quantification of glycoprotein, please contact us to obtain more information.
Associated Services
Protein Expression and Purification: To support your glycoproteomic studies, we provide high-quality protein expression and purification services, ensuring you have the pure protein samples required for accurate analysis.
Structural Elucidation: For a deeper understanding, we offer detailed structural analysis of individual glycans attached to your proteins, including monosaccharide composition, linkage analysis, and branching patterns.
Reference
- Chen, M.; et al. Comparative site-specific N-glycoproteome analysis reveals aberrant N-glycosylation and gives insights into mannose-6-phosphate pathway in cancer. Communications Biology. 2023, 6(1): 48. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




